{
  "docId": "019de073-7b6a-72bb-8d98-812d56d63617",
  "docSlug": "f8b2787992eb3375620f74057447d0c9",
  "documentTitle": "Aravive | Investor Presentation Deck | 39 slides",
  "authorId": "aravive",
  "authorName": "Aravive",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 39,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Includes a bifurcation diagram illustrating the relationship between SNAIL and ZEB mRNA levels in different cell phenotypes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7b6a-72bb-8d98-812d56d63617/6",
  "deckHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617",
  "deckJsonHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617.json",
  "deckAnchorHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.72,
        "y": 0.28
      },
      "kind": "chart",
      "text": "Bifurcation diagram showing ZEB mRNA vs SNAIL molecules for E, E/M, and M phenotypes.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dcc577d7-1ca0-4a40-a404-941a3a29d000",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.65,
        "x": 0.03,
        "y": 0.23
      },
      "kind": "list",
      "text": "Batiraxcept demonstrates single agent activity in preclinical models which have homogeneous, metastatic tumor cells. Human tumors display epithelial-mesenchymal heterogeneity. Cells within the same tumor can exhibit different phenotypes: epithelial (E); mesenchymal (M); or one or more hybrid epithelial-mesenchymal phenotypes. Phenotypic heterogeneity is a hallmark of aggressive cancer behavior and a clinical challenge. Chemotherapies, targeted therapies and IO therapies have all been reported to increase the GAS6/AXL signaling. Effective treatment requires drug(s) to affect both E and M populations. Batiraxcept does not target rapidly dividing epithelial cells nonspecifically like chemotherapeutics but targets mesenchymal, invasive cells. Need agent to inhibit/decrease epithelial cell growth as well as inhibit/prevent mesenchymal cell growth.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fdc13b75-a25b-4d50-a376-af98547cc069",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.03,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "1 PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007619 February 10, 2020 2 Safa, J Cancer Metastasis Treat 2020;6:36 3 Biomolecules 2022, 12, 348. https://doi.org/10.3390/biom12030348",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d3a66a9-1f65-4611-bdc0-003ad0804031",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Effective Treatment of Human Tumors Requires Drugs that Target Non-metastatic and Metastatic Tumor Cells",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d23e2255-ae3a-4d5f-9e1b-e5c962438279",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 4,
      "beatId": "28f3f743-e3cf-4d52-acd4-476055b1969c",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "Slides 4-6 highlight the problems associated with GAS6/AXL signaling and the need for effective treatment",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "2bad4849-76ce-484b-ad2f-532281679f0e",
      "evidence": "The document highlights the limitations of current treatments and the potential benefits of targeting GAS6/AXL signaling",
      "position": 0,
      "objective": "What is the cost of not addressing GAS6/AXL signaling in cancer treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}